NewsBenzinga캠프4 테라퓨틱스, CMP-002의 글로벌 1/2상 ASCEND 임상시험을 유럽연합 시험기관에서 시작하기 위해 다수의 EU 국가 규제 당국 및 윤리위원회로부터 CTA 승인 획득 캠프4 테라퓨틱스, CMP-002의 글로벌 1/2상 ASCEND 임상시험을 유럽연합 시험기관에서 시작하기 위해 다수의 EU 국가 규제 당국 및 윤리위원회로부터 CTA 승인 획득 Benzinga 2026.10.27 12:06 (GMT+0) Open on Benzinga Other news Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Evernorth Has Written Down Its Pre-Listing XRP Holdings by 60%
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory